Latest Information Update: 19 Oct 2000
At a glance
- Originator Sankyo
- Class Neuroprotectants
- Mechanism of Action Muscarinic M1 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued CNS disorders
Most Recent Events
- 19 Oct 2000 Discontinued-Preclinical for CNS disorders in Japan (Unknown route)
- 14 Sep 1999 New profile
- 14 Sep 1999 Preclinical development for CNS disorders in Japan (Unknown route)